Marc-André Blais

Direktor/Vorstandsmitglied bei Prognomix, Inc.

Health Technology

Aktive Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Pavel Hamet	M	-	Prognomix, Inc. Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.	19 Jahre
Johanne Tremblay	M	-	Prognomix, Inc. Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.	-
Francesco Bellini	M	77	Prognomix, Inc. Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.	-
Normand Balthazard	M	-	Prognomix, Inc. Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.	-
Lynda Desroches	F	-	Prognomix, Inc. Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.	-
John Chalmers	M	-	Prognomix, Inc. Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.	-
Stephen Harrap	M	-	Prognomix, Inc. Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.	-
Michel Marre	M	-	Prognomix, Inc. Prognomix, Inc. Pharmaceuticals: GenericHealth Technology Prognomix, Inc. develops market molecular diagnostic kits for testing of diabetes complications. Its products include PGX IR01, PGx GR01, PGx CD01 and PGx IR02. The firm focuses on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. The company was founded by Johanne Tremblay and Pavel Hamet in 2005 and is headquartered in Montreal, Canada.	-